JP2017524740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524740A5 JP2017524740A5 JP2017525320A JP2017525320A JP2017524740A5 JP 2017524740 A5 JP2017524740 A5 JP 2017524740A5 JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017524740 A5 JP2017524740 A5 JP 2017524740A5
- Authority
- JP
- Japan
- Prior art keywords
- affinity matrix
- heterodimer
- range
- polypeptide
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 24
- 239000000833 heterodimer Substances 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000000872 buffer Substances 0.000 claims 7
- 239000000710 homodimer Substances 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000003196 chaotropic effect Effects 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012539 chromatography resin Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000012433 multimodal chromatography Methods 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 claims 1
- 229940005991 chloric acid Drugs 0.000 claims 1
- 239000005289 controlled pore glass Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000012515 MabSelect SuRe Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 | |
| US62/029,463 | 2014-07-26 | ||
| PCT/US2015/041936 WO2016018740A2 (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524740A JP2017524740A (ja) | 2017-08-31 |
| JP2017524740A5 true JP2017524740A5 (enExample) | 2020-01-30 |
| JP6702967B2 JP6702967B2 (ja) | 2020-06-03 |
Family
ID=53836215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525320A Active JP6702967B2 (ja) | 2014-07-26 | 2015-07-24 | 二重特異性抗体のための精製プラットフォーム |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10626142B2 (enExample) |
| EP (2) | EP3912987B9 (enExample) |
| JP (1) | JP6702967B2 (enExample) |
| KR (1) | KR102440737B1 (enExample) |
| CN (1) | CN107074906B (enExample) |
| AR (1) | AR101262A1 (enExample) |
| AU (1) | AU2015298156B2 (enExample) |
| DK (2) | DK3912987T3 (enExample) |
| EA (1) | EA036154B1 (enExample) |
| ES (2) | ES2942533T3 (enExample) |
| FI (1) | FI3912987T3 (enExample) |
| IL (1) | IL255198B (enExample) |
| MX (1) | MX377558B (enExample) |
| MY (1) | MY187051A (enExample) |
| PL (2) | PL3912987T3 (enExample) |
| SG (2) | SG11201700157VA (enExample) |
| TW (1) | TWI704155B (enExample) |
| WO (1) | WO2016018740A2 (enExample) |
| ZA (1) | ZA201700622B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| US10294306B2 (en) * | 2015-05-28 | 2019-05-21 | Bio-Rad Laboratories, Inc. | Affinity ligands and methods relating thereto |
| AU2016381992B2 (en) * | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| CR20180554A (es) | 2016-04-28 | 2019-01-10 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| EP4549463A3 (en) * | 2016-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
| WO2018038469A1 (ko) * | 2016-08-20 | 2018-03-01 | (주)아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| KR101933656B1 (ko) | 2016-08-20 | 2018-12-28 | (주) 아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| CN119161488A (zh) | 2017-11-01 | 2024-12-20 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| GB201805142D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| MY207066A (en) * | 2018-08-17 | 2025-01-28 | Regeneron Pharma | Method and chromatography system for determining amount and purity of a multimeric protein |
| SG11202102713TA (en) * | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
| WO2020066270A1 (ja) * | 2018-09-28 | 2020-04-02 | 株式会社カネカ | κ鎖可変領域を含む抗体および／または抗体断片の製造方法 |
| JP2022514122A (ja) | 2018-10-31 | 2022-02-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質を同定及び定量化する方法及びシステム |
| CA3110377A1 (en) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
| CN112996801A (zh) * | 2018-11-26 | 2021-06-18 | 北卡罗来纳州大学 | 用于捕获宿主细胞蛋白的肽配体 |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| IL319262A (en) | 2018-12-24 | 2025-04-01 | Sanofi Sa | Multispecific FAB pseudoproteins bind |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| EP3983015A1 (en) | 2019-06-11 | 2022-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
| WO2020252260A1 (en) * | 2019-06-13 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Methods for removing undesired components during multistage chromatographic processes |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| CA3163017A1 (en) * | 2019-12-26 | 2021-07-01 | Daehae SONG | Method for purifying biologically active peptide by using protein a affinity chromatography |
| KR102834449B1 (ko) | 2019-12-27 | 2025-07-15 | 케이에스광학주식회사 | 투명한 방탄 적층 구조물 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| JP2024504388A (ja) * | 2021-01-25 | 2024-01-31 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
| CN118414350A (zh) * | 2021-10-19 | 2024-07-30 | 阿特根公司 | 纯化具有igg fc结构域的融合蛋白的方法 |
| WO2023247468A2 (en) * | 2022-06-22 | 2023-12-28 | Puridify Limited | Kappa light chain-binding convection matrix |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
| WO2025073922A1 (en) * | 2023-10-04 | 2025-04-10 | Sartorius Bia Separations D.O.O. | Enhanced chromatographic separations of components in a mixture by employing chaotropic elution |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2025131519A1 (en) * | 2023-12-21 | 2025-06-26 | Cytiva Bioprocess R&D Ab | Antibody separation with a vh3 binding separation matrix |
| WO2025173342A1 (ja) * | 2024-02-13 | 2025-08-21 | Jsr株式会社 | Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法 |
| WO2026075981A1 (en) * | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Methods of analyzing heterodimeric proteins |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| WO2000018435A1 (de) | 1998-09-25 | 2000-04-06 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| ZA200710330B (en) | 2005-06-17 | 2009-12-30 | Wyeth Corp | Methods of purifying FC region containing proteins |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
| US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2785414C (en) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| EP2500073A1 (en) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| EP3517548A1 (en) * | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
-
2015
- 2015-07-21 AR ARP150102301A patent/AR101262A1/es active IP Right Grant
- 2015-07-23 TW TW104123813A patent/TWI704155B/zh active
- 2015-07-24 SG SG11201700157VA patent/SG11201700157VA/en unknown
- 2015-07-24 MX MX2017001217A patent/MX377558B/es active IP Right Grant
- 2015-07-24 EP EP21170436.6A patent/EP3912987B9/en active Active
- 2015-07-24 MY MYPI2017700080A patent/MY187051A/en unknown
- 2015-07-24 JP JP2017525320A patent/JP6702967B2/ja active Active
- 2015-07-24 DK DK21170436.6T patent/DK3912987T3/da active
- 2015-07-24 KR KR1020177003803A patent/KR102440737B1/ko active Active
- 2015-07-24 SG SG10201900661YA patent/SG10201900661YA/en unknown
- 2015-07-24 US US14/808,171 patent/US10626142B2/en active Active
- 2015-07-24 ES ES21170436T patent/ES2942533T3/es active Active
- 2015-07-24 WO PCT/US2015/041936 patent/WO2016018740A2/en not_active Ceased
- 2015-07-24 AU AU2015298156A patent/AU2015298156B2/en active Active
- 2015-07-24 EA EA201790247A patent/EA036154B1/ru not_active IP Right Cessation
- 2015-07-24 PL PL21170436.6T patent/PL3912987T3/pl unknown
- 2015-07-24 EP EP15750182.6A patent/EP3172221B1/en active Active
- 2015-07-24 DK DK15750182.6T patent/DK3172221T3/da active
- 2015-07-24 FI FIEP21170436.6T patent/FI3912987T3/fi active
- 2015-07-24 ES ES15750182T patent/ES2881026T3/es active Active
- 2015-07-24 PL PL15750182T patent/PL3172221T3/pl unknown
- 2015-07-24 CN CN201580040494.9A patent/CN107074906B/zh active Active
-
2017
- 2017-01-25 ZA ZA2017/00622A patent/ZA201700622B/en unknown
- 2017-10-22 IL IL255198A patent/IL255198B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524740A5 (enExample) | ||
| FI3912987T3 (fi) | Puhdistusalusta bispesifisille vasta-aineille | |
| JP2012515160A5 (enExample) | ||
| JP2014501758A5 (enExample) | ||
| JP2014500311A5 (enExample) | ||
| JP2016502843A5 (enExample) | ||
| JP2018510867A5 (enExample) | ||
| JP2017086090A5 (enExample) | ||
| JP2019033754A5 (enExample) | ||
| JP2018023398A5 (enExample) | ||
| JP2015506926A5 (enExample) | ||
| JP2015512893A5 (enExample) | ||
| JP2015537212A5 (enExample) | ||
| JP2015227386A5 (enExample) | ||
| JP2013530156A5 (enExample) | ||
| Holstein et al. | Mobile phase modifier effects in multimodal cation exchange chromatography | |
| JP2012522736A5 (enExample) | ||
| Pezzini et al. | A comprehensive evaluation of mixed mode interactions of HEA and PPA HyperCel™ chromatographic media | |
| TWI660774B (zh) | 吸附材料 | |
| Wang et al. | Evaluation of mixed-mode chromatographic resins for separating IgG from serum albumin containing feedstock | |
| JP2011500757A5 (enExample) | ||
| CN104226283A (zh) | 聚乙烯醇涂覆型色谱固定相及其制备方法与应用 | |
| Tao et al. | Adsorption of deamidated antibody variants on macroporous and dextran-grafted cation exchangers: II. Adsorption kinetics | |
| Nian et al. | Void exclusion of antibodies by grafted-ligand porous particle anion exchangers | |
| JP2015518489A5 (enExample) |